Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit M Oza

Showing results (31-40 of 250) with videos related to

Pageof 25
Sort By:
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in trials of cancer treatment: the past, present, and futureMichelle K Wilson, Katherine Karakasis, Amit M Oza
Cancer|June 17, 2015
Discrepancies in drug approvals: A global dilemmaMichelle K Wilson, Katherine Karakasis, Amit M Oza
Future Oncology (London, England)|June 2, 2018
The role of niraparib for the treatment of ovarian cancerJosee-Lyne Ethier, Stephanie Lheureux, Amit M Oza
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2024
Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological MissileAna C Veneziani, Suku Sneha, Amit M Oza
Cancers|June 28, 2023
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker DiscoveryIlaria Colombo, Katherine Karakasis, Sneha Suku, et al.
Clinical Medicine Insights. Oncology|August 2, 2023
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerEduardo Gonzalez-Ochoa, Ana C Veneziani, Amit M Oza
Nature Cancer|February 5, 2022
Advances in ovarian cancer, from biology to treatmentMichelle McMullen, Katherine Karakasis, Robert Rottapel, et al.
Cancers|June 21, 2020
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian CancerMichelle McMullen, Katherine Karakasis, Ainhoa Madariaga, et al.
Expert Opinion on Drug Safety|June 9, 2015
Safety evaluation of olaparib for treating ovarian cancerStephanie Lheureux, Valerie Bowering, Katherine Karakasis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 30, 2021
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinomaJoyce Liu, Amit M Oza, Nicoletta Colombo, et al.
Pageof 25

Showing results (31-40 of 250) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in trials of cancer treatment: the past, present, and futureMichelle K Wilson, Katherine Karakasis, Amit M Oza
Cancer|June 17, 2015
Discrepancies in drug approvals: A global dilemmaMichelle K Wilson, Katherine Karakasis, Amit M Oza
Future Oncology (London, England)|June 2, 2018
The role of niraparib for the treatment of ovarian cancerJosee-Lyne Ethier, Stephanie Lheureux, Amit M Oza
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2024
Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological MissileAna C Veneziani, Suku Sneha, Amit M Oza
Cancers|June 28, 2023
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker DiscoveryIlaria Colombo, Katherine Karakasis, Sneha Suku, et al.
Clinical Medicine Insights. Oncology|August 2, 2023
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerEduardo Gonzalez-Ochoa, Ana C Veneziani, Amit M Oza
Nature Cancer|February 5, 2022
Advances in ovarian cancer, from biology to treatmentMichelle McMullen, Katherine Karakasis, Robert Rottapel, et al.
Cancers|June 21, 2020
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian CancerMichelle McMullen, Katherine Karakasis, Ainhoa Madariaga, et al.
Expert Opinion on Drug Safety|June 9, 2015
Safety evaluation of olaparib for treating ovarian cancerStephanie Lheureux, Valerie Bowering, Katherine Karakasis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 30, 2021
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinomaJoyce Liu, Amit M Oza, Nicoletta Colombo, et al.
Pageof 25